Pharma News

A pioneering study has revealed new insights into the role of gastric bacteria in stomach cancer development that could pave the way for a more effective treatment of pre-cancer according to a study published today in Helicobacter.

A ‘chasm of misunderstanding and miscommunication’ is often experienced between clinicians and patients, leading to autoimmune diseases such as lupus and vasculitis being wrongly diagnosed as psychiatric or psychosomatic conditions, with a profound and lasting impact on patients, researchers have found.

Utilizing a novel diagnostic test for peripheral blood immunophenotyping, researchers were able to identify the specific sources of inflammation triggering the novel skin disease and reverse symptoms with targeted treatments.

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave the way for precision-medicine based diagnostic testing and targeted treatment.

Hormones may be leveraged to treat and prevent signs of aging such as wrinkles and hair graying, according to a new study published in the EndocrineSociety journal Endocrine Reviews.

Until now, only a limited number of hormones, mainly topical retinoids (retinol and tretinoin) and estrogen which is typically used to treat side effects of menopause, have been used in clinical practice as anti-skin aging compounds. This study reviews a new class of hormones and their anti-aging properties.

New findings question assumptions of cancer formation in individuals with the cancer-predisposition syndrome, neurofibromatosis type 1, and offer hope for a personalised approach to early cancer recognition including for those with similar conditions.

the U.S. Food and Drug Administration approved Ctexli for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.